Month: April 2022

RT @ThomasCiullaMD: Just published: Disease progression pathways of wet AMD: op…

RT @ThomasCiullaMD: Just published: https://t.co/pGZQQVEySc Disease progression pathways of wet AMD: opportunities for new target discovery… Source by Thomas Ciulla, MD, MBA Return to main website.

Looking forward to ARVO 2022 meeting next week. Check out these excellent presen…

Looking forward to ARVO 2022 meeting next week. Check out these excellent presentations providing insights on #suprachoroidal delivery of investigational agents, a corticosteroid, and a #genetherapy. #xipere #uveitis #AMD #diabeticretinopathy #retina #biotech #clinicalresearch https://t.co/havK3tYkqD Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazing…


RT @ThomasCiullaMD: This webinar on #suprachoroidal delivery features an amazingly talented team:


Source by Thomas Ciulla, MD, MBA

Return to main website.

Just published: This work supports the favorable targeting, compartmentalizatio…

Just published: This work supports the favorable targeting, compartmentalization and durability of the first FDA-approved #suprachoroidal therapy…#eyes #retina #xipere #uveitis https://t.co/LQ0o7aZkmS Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinaToday: How Will Suprachoroidal Injections Alter the Treatment Landscap…

RT @RetinaToday: How Will Suprachoroidal Injections Alter the Treatment Landscape? View more from @EvolveMedEd: https://t.co/NjPvvseOWE htt… Source by Thomas Ciulla, MD, MBA Return to main website.

Our clinical study, highlighting the need for better therapy, was picked up by O…


Our clinical study, highlighting the need for better therapy, was picked up by Ophthalmology Advisor: Longer Term Anti-VEGF Outcomes in Neovascular AMD, Diabetic and Vein Occlusion Related Macular Edema:
#retina #AMD #diabeticretinopathy https://t.co/uUMf8y1V2M


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Our recent paper was “Editor’s Choice”: This post hoc analys…

RT @ThomasCiullaMD: Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ModernRetina: @BauschRetina and @clearsidebio are rolling out the new therap…

RT @ModernRetina: @BauschRetina and @clearsidebio are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the t… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinalPhys: Read about the commercial launch of Xipere and more industry ne…


RT @RetinalPhys: Read about the commercial launch of Xipere and more industry news in the eUpdate: https://t.co/opmf3Pc1D6


Source by Thomas Ciulla, MD, MBA

Return to main website.

This webinar on #suprachoroidal delivery features an amazingly talented team: …

This webinar on #suprachoroidal delivery features an amazingly talented team: https://t.co/S0LmnWUSqm Source by Thomas Ciulla, MD, MBA Return to main website.